A Double-blind, Randomized Controlled Trial of Ciplukan (Physalis angulata Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers in Scleroderma Patients

Sumartini Dewi, Harry Isbagio, Erni Hernawati Purwaningsih, Nyoman Kertia, Rianto Setiabudy, Siti Setiati


Background: scleroderma is an autoimmune disease characterized by organ fibrosis, resistant to standard treatment. It is suspected the addition of Physalis angulata Linn. (Ciplukan) extract as adjuvant therapy can improve the scleroderma skin fibrosis. The aim at this study is to evaluate the effect of ciplukan extract as adjuvant on scleroderma skin fibrosis in standard therapy, based on modified Rodnan skin scale (MRSS), inflammatory biomarkers, immunology and serum fibrosis. Methods: double-blind, randomized clinical trial was performed in scleroderma patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015−March 2017 who met the selection criteria and continued to receive standard therapy. The subjects were randomly allocated into two groups: the study group received the ciplukan  extract 3 x 250 mg / day for 12 weeks and the placebo group. Examination of MRSS, ESR, P1NP, BAFF and sCD40L was performed every 4 weeks until the end of the study. Results: fifty-nine subjects completed the study. They consisted of 29 subjects of the treatment group and 30 of the placebo group, with an average age of 41 (SD 9) years, the proportion of women: male = 9 : 1. There was a significant improvement of skin fibrosis in the study group with a highly significant decrease in MRSS (35.9% VS 6.3%, p <0.001) and a relative decrease in P1NP levels (17.8% VS 0.7%, p = 0.002). No decrease in ESR, BAFF and sCD40L levels in both groups. There was a weak but significant positive correlation between MRSS with P1NP levels (r = 0.236, p = 0.036). Conclusion: Ciplukan extract with dose 3 x 250 mg for 12 weeks as adjuvant on scleroderma standard therapy alleviates skin fibrosis significantly based on MRSS and P1NP levels.


Physalis angulata Linn; modified Rodnan’s skin score (MRSS); erythrocyte sedimentation rate (ESR); procollagen type-1 N terminal proteinase (P1NP); scleroderma


Hunzelmann N, Brinckmann J. What are the new milestones in the pathogenesis of systemic sclerosis? Ann Rheum Dis. 2010;69 Suppl 1:52-6.

Khanna, Dhanita. Diagnosis and treatment of systemic and localized scleroderma. 2011.

Bogna GG, Mariusz P. Oxidative damage and antioxidative therapy in systemic sclerosis. Hindawi Publishing Corp. Mediators of Inflam. 2014:1-11.

Gabrielli A, Svegliati S, Moroncini G, Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J. 2012;6 (Suppl 1: M4):87-95.

Yamamoto T. Autoimmune mechanisms of scleroderma and a role of oxidative stress. Landes Bioscience. 2011;2(1):4-10.

Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: A report from The EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620-8.

Pinto NB, Morais TC, Carvalho KM, et al. Topical anti-inflammatory potential of Physalin E from Physalis angulata on experimental dermatitis in mice. Phytomedicine. 2010;17(10):740-3.

Mahalaksmi AM, Nidavani RB. Physalis angulata L. An Ethnopharmacological review. Indo Am J Pharm Res. 2014;4(3):1479-86.

Kusumaningtyas RW, Limandha P. Potential of Ciplukan/Physalis angulata as source of functional ingredient. Proc Chem. 2015;14:367– 72.

Soares MB, Bellintani MC, Ribeiro IM, Tomassini TC, Ribeiro dos Santos R. Inhibition of macrophage activation and lipopolysaccaride-induced death by seco-steroids purified from Physalis angulata L. Eur J Pharm. 2003;459(1):107-12.

Soares MB, Brustolim D, Santos LA, et al. Physalins B, F and G, seco-steroids purified from Physalis angulata L., inhibit lymphocyte function and allogeneic transplant rejection. Int Immun Pharm. 2006;6(3):408-14.

Vieira AT, Pinho V, Lepsch LB, et al. Mechanisms of the antiinflammatory effects of the natural secosteroids physalins in a model of intestinal ischaemia and reperfusion injury. Br J Pharm. 2005;146(2):244-51.

Minier T. Assesment of disease activity and evaluation of clinical parameters and biomarkers in systemic sclerosis. University of Pecs; 2011.

Distler JH, Allanore Y, Avouac J, et al. EULAR scleroderma trials and research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis. 2009;68(2):163-8.

Vincent S, Sumartini D, Rachmat GW. Correlation between serum procollagen type 1 N-terminal propeptide level with modified Rodnan skin score in systemic sclerosis patients. Indones J Rheum. 2017;9(2):8-12.

Ponticos M, Papaioannou I, Xu S, et al. Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum. 2015;67(1):243-53.

François A, Chatelus E, Sibilia J, et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther. 2013;15:168-73.

Abdo MS, Mohammed HR, Raslan HM, Gaber SM. Serum B-cell activating factor assessment in a population of Egyptian patients with systemic sclerosis. Internat J Rheum Dis. 2013;16(2):148-56.

Fawzy SM, Gheita TA, El-Nabarawy E, El-Demellawy HH, Shaker OG. Serum BAFF level and its correlations with various disease parameters in patients with systemic sclerosis and systemic lupus erythematosus. Egypt Rheum. 2011;33(1):45-51.

Lapinska A, Kowal K, Chwiecko J, et al. CD40L May contribute to the pathogenesis of systemic sclerosis through the regulation of Eicosanoid production in mononuclear cells. Ann Rheum Dis. 2009;68(3):272-8.

Abignano G, Buch M, Emery P, Del Galdo F. Biomarkers in the management of scleroderma: an update. Curr Rheum Rep. 2011;13(1):4-12.

Moinzadeh P, Denton CP, Abraham D, et al. Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Derm Vener. 2012;26(3):267-76.

Susanti RF, Kurnia K, Vania A, Reynaldo IJ. Total phenol, flavanoid and antioxidant activity of physalis angulata leaves extract by subcritical water extraction. Mod App Sci. 2015;9(7):190-8.

Zubair MF, Anibijuwon II, Ameen OM, Abdulrahim HA. Secondary metabolite constituents and antibacterial potency of Physalis angulata against some clinical isolates. Nigerian J Biochem Mol Biol. 2014;29(2):161-5.

Porika R PS, Lunavath V, Mamidala E. Preliminary phytochemical investigation and TLC analysis of Physalis angulata fruit extract. J Pharm and Bio Sci.2014;9(2):11-4.

Dooley A BK, Abraham DJ. Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants. Cardio Res Pract. 2012;52(8):9-18.

Krishna M. VR, Kumar EM. In vitro determination of antioxidant activity of Physalis angulata Linn. Int J Pharm Bio Sci. 2013;4(3):541-9.

Full Text: PDF


  • There are currently no refbacks.